A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease

NCT06413511 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Autoimmune Diseases

Interventions

BIOLOGICAL: Belantamab

Sponsor

GlaxoSmithKline